drugset / Trial / NCT04487691

Nebulized PL for Post-COVID-19 Syndrome

NCT04487691

Terminated 1 enrolled Regenexx, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate and compare nebulized platelet lysate to placebo control of saline administered via handheld nebulizer 1x daily for eight weeks to determine effect on lung function in patients with post-COVID-19 ARDS syndrome.

Timeline

Start
2020-12-08
Primary completion
2021-06-15
Completion
2021-06-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Platelet Lysate Unknown 2 ml Inhaled

Indications